The finding offers the chance for more women who have been diagnosed with cancer to restore their fertility following chemotherapy or radiotherapy – cancer treatments that can seriously damage the ovaries, often permanently. The findings were presented at the 24th annual meeting of the European Society of Human Reproduction and Embryology in Barcelona today (Monday).
At present, women who have been diagnosed with cancer may want to have some of their eggs collected and frozen in order to give them an opportunity of having children once their cancer treatment has finished. However, conventional protocols involve starting ovarian stimulation only at the beginning of a woman’s menstrual cycle (the day that menstruation starts). Therefore, if the cancer diagnosis is made at any other time in the cycle, a woman could wait up to six weeks before it would be possible to collect eggs (or oocytes) after ovarian stimulation. For many women, six weeks is too long to wait before starting cancer treatment.
Dr Michael von Wolff, vice-director of the Department of Gynaecological Endocrinology and Reproduction Medicine at the University of Heidelberg, Germany, told a conference news briefing: “Depending on what phase of her menstrual cycle a woman is in when she receives a cancer diagnosis, it can take between two and six weeks to start ovarian stimulation and collect oocytes. Two weeks is an acceptable amount of time in many diseases to wait before starting a cancer treatment such as chemotherapy, but three to six weeks is far too long.”
The researchers conducted a pilot study in 40 women in 2007 to see whether it would be possible to initiate ovarian stimulation during the luteal phase (the phase in the menstrual cycle from ovulation to the start of the next menstruation), without first having to give drugs to stop the luteal phase.
“Although other research has looked at giving medication to stop the luteal phase and then starting regular IVF treatment a few days later, to my knowledge, nobody has ever started ovarian stimulation immediately, without delay, in the luteal phase, either for IVF or for cancer patients,” said Dr von Wolff. “This is because, in traditional IVF, ovarian stimulation has to be started at the beginning of the menstrual cycle, otherwise the endometrium is inadequately developed and a fertilised oocyte would be unable to implant successfully.”
The researchers started ovarian stimulation in 28 patients in the proliferative phase of their cycle (the time from the start of menstruation to ovulation) using standard stimulation medications (GnRH-analogues and human menopausal gonadtropin, HMG, or follicle stimulation hormone, FSH). In a second group of 12 women they started stimulation during the luteal phase, using GnRH-antagonists and recombinant FSH (a synthetic form of FSH) in order to hasten the end of the luteal phase (luteolysis) and promote the development of new follicles containing oocytes.
The average time of ovarian stimulation was 10.3 days in the first group and 11.4 days in the second group. A mean average of 13 oocytes were collected from the first group and 10 from the second group. Nearly 77% and 73% of the oocytes were mature in the respective groups, and after intracytoplasmic sperm injection (ICSI), 70% and 75% of the oocytes were fertilised respectively.
The researchers found that if ovarian stimulation was started in the second group during ovulation, then the luteal phase stopped after five days, and if stimulation was started in the mid-luteal phase, then it stopped within two days, enabling new follicles to start maturing.
Dr von Wolff said: “We found that the ovarian stimulation regime for patients in the luteal phase was successful in triggering the end of the luteal phase and the recruitment of a new cohort of follicles. The number of oocytes obtained after stimulation in the luteal phase was slightly but not significantly lower than those obtained after stimulation in the proliferative phase. However the oocyte quality was the same in both groups. This pilot study demonstrates for the first time that mature oocytes can be obtained before cancer therapy within a time frame of two weeks.
“This new protocol would enable patients with cancers such as breast cancer and Hodgkin lymphoma to have ovarian stimulation and oocyte collection. Waiting for two weeks before they start cancer treatment is acceptable for most patients while this process happens. For breast cancer patients, this technique can be combined with the anti-oestrogen drug letrozole. Furthermore, this protocol allows the combination of freezing and storing both ovarian tissue and oocytes, which results in the women having a higher chance of achieving pregnancy if their cancer treatment causes ovarian failure.”
Dr von Wolff said information about these new techniques needed to be disseminated to oncologists so that they were aware of the options available to their patients to help them preserve their fertility. National networks of specialised centres capable of carrying out these techniques should be established, he concluded.
Sarah De Potter | alfa
Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University
NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.
In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...
19.03.2018 | Event News
16.03.2018 | Event News
13.03.2018 | Event News
22.03.2018 | Trade Fair News
22.03.2018 | Earth Sciences
22.03.2018 | Earth Sciences